RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
CAR T-Cell therapy trial for lymphoma pulled before it started
Disease control TerminatedThis study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but i…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 23, 2026 22:34 UTC
-
New hope for lymphoma patients: drug duo aims to control relapsed disease
Disease control OngoingThis Phase 3 study tests whether a new combination of drugs (mosunetuzumab plus lenalidomide) works better than the current standard (rituximab plus lenalidomide) for people with follicular lymphoma that has returned after at least one prior treatment. About 478 participants will…
Matched conditions: RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC